Share on StockTwits

Stock analysts at Maxim Group increased their price objective on shares of Stemcells (NASDAQ:STEM) from $2.50 to $5.00 in a report issued on Friday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 139.23% from the company’s current price.

Stemcells (NASDAQ:STEM) opened at 2.09 on Friday. Stemcells has a one year low of $1.15 and a one year high of $2.10. The stock’s 50-day moving average is $1.38 and its 200-day moving average is $1.38. The company’s market cap is $116.0 million.

Stemcells (NASDAQ:STEM) last released its earnings data on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Analysts expect that Stemcells will post $-0.60 EPS for the current fiscal year.

STEM has been the subject of a number of other recent research reports. Analysts at Chardan Capital reiterated a “positive” rating on shares of Stemcells in a research note on Tuesday. Analysts at Edison Investment Research reiterated a “neutral” rating on shares of Stemcells in a research note on Thursday, April 17th.

StemCells, Inc (NASDAQ:STEM) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.